Efficacy of Intravenously Administered Gepotidacin in Cynomolgus Macaques following a Francisella tularensis Inhalational Challenge-Reference-Cited by-同舟云学术

Efficacy of Intravenously Administered Gepotidacin in Cynomolgus Macaques following a Francisella tularensis Inhalational Challenge

Published:2023-05-17 Issue:5 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Jakielaszek Charles¹^ORCID,Hilliard Jamese J.¹,Mannino Frank¹,Hossain Mohammad¹,Qian Lian¹,Fishman Cindy¹^ORCID,Chou Ying-Liang²,Henning Lisa²,Novak Joseph²,Demons Samandra³,Hershfield Jeremy³,O’Dwyer Karen¹^ORCID

Affiliation:

1. GSK Pharmaceuticals, Collegeville, Pennsylvania, USA

2. Battelle Biomedical Research Center (BBRC), Columbus, Ohio, USA

3. U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA

Abstract

Francisella tularensis ( F. tularensis ) is a Centers for Disease Control (CDC) category “A” Gram-negative biothreat pathogen. Inhalation of F. tularensis can cause pneumonia and respiratory failure and is associated with high mortality rates without early treatment.

Funder

US | Defense Threat Reduction Agency

GlaxoSmithKline

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01381-22

Reference39 articles.

1. Tularemia

2. The Divergent Intracellular Lifestyle of Francisella tularensis in Evolutionarily Distinct Host Cells